Treatment-emergent adverse events (AEs) were generally well-balanced, but there were slightly more Grade 3 AEs, as well as more dose delays and reductions with sacituzumab.
No new safety signals were identified with extended follow-up.
* Key AEs to be mindful of: Neutropenia.
Lisa Park is a leading technology journalist with 11 years of experience covering Silicon Valley, emerging technologies, and digital innovation. Lisa holds a Master’s in Computer Science and Her expertise spans artificial intelligence, blockchain technology, cybersecurity, and venture capital. She has exclusive access to tech executives, startup founders, and industry insiders, making her a trusted voice in technology reporting.
This news is powered by News Directory 3 
